Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.44 +0.15 (+0.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Here's Why Arcus Biosciences Stock Is Rising Today
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise. 
Via The Motley Fool
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday. 
Via Investor's Business Daily
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Stock Profile: Roche Holding AG ADR
Roche maintains a healthy balance sheet with $13.9 billion in cash and investments and $12.5 billion in long-term debt as of 12/31/2020. 
Via Talk Markets
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's... 
Via Benzinga
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat... 
Via Benzinga
Exposures COVID-19 Product Safety
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
Exposures Product Safety
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic... 
Via Benzinga
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
Happy Friday
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
From Genentech
Via Business Wire
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
Exposures Product Safety
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting... 
Via Benzinga
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.